Juan José Pérez Villar, CEO of Leadartis: "With the support of CDTI Innovation aspire to be a reference in treatments" inmuno-oncológicos
Leadartis is a small biotechnology company in preclinical phase aimed at developing molecules that are likely to provoke immune responses antitumorales safe and effective and long-term unemployment in patients with different types of cancer
As inmunólogo, Juan José Pérez Villar, CEO and partner of this company has devoted much of their careers to the development of clinical development projects on inmuno-oncología for american multinationals.
I would like to highlight ", explains Juan José Pérez Villar, thatLeadartishas a team of highly qualified professionals such as the Sard. Marta Compte Grau, director of R & D, and female researchers senior Susana Frago, Rocío Navarro and Amaia Carrillo, expert in regulatory environment. The company is advised by expert opinion leaders such as dr. Luis Álvarez-vallina, chairman of the unit of Clinical research H12O-CNIO Allergies, cancer and dr. Luis Paz-Ares, head of oncology Form the Hospital 12 de Octubre de Madrid (H12O), reference centre for oncological tratramientos ".
Model of a virtual Trimerbody
Technological platform
Over the past seven years, this micropyme has developed a patented technology platform and known as TrimerbodyTM with generated antibodies biespecíficos inmuno-oncológicos treatments as different types of aggressive tumours and in an advanced stage (metastasis) such as breast carcinomas, lung, colon, head and neck.
Product by Leadartis
Inmuno-oncología
"despite the great strides made in recent years, there is a great need to obtain new safest and most effective treatments about cancer and help them deal more than 100 different types of cancer and the more than 35 million new patients diagnosed each year".
“ the needs of oncological market are very high, affecting all types of cancer, especially in advanced stage of the disease where many of the patients do not have effective alternative. This is a sector with high demand for innovative treatments and very segmented. In recent years, some of the oncology treatments that are making large investments in R & D is allergies as biological therapy to stimulate the immune system in a context of cancerous ”.
“ however, the limited existing modalities of, there are currently no be appropriate, either by the adverse effects or by the low response tase they produce. Our technological platform Trimerbody is an innovative format, Unique in the world, biespecifico antibody we have achieved and patented internationally at the beijing platform, the mechanism of action and, more recently, product ”.
“ today, we have managed successfully developing our candidate, LEAD-452 in preclinical numerous models of cancer where we have demonstrated the eradication of advanced tumours lung, colon and breast cancer in a very high percentage along with generating anti-tumoral immune memory. In Addition, we have seen their safety as well as their appropriate in primates-no-humanos pharmacokinetic characteristics (macacos). In the next 12 months, we look forward to beginning the first clinical studies in patients with the aforementioned without therapeutical alternative cancers where other terápias have failed. Without doubt, be a long and costly process to obtain approval for its administration in patients ”.
"if we manage to get the results to the pre-clinical LEAD-452, will be a “ game changer ” both for their assistance to patients and their families and their cost benefit to the health and society at large".
Leadartis personnel handling equipment for the analysis of quality of its antibodies
Financing of CDTI Innovation
The result of their continued activity in r & D, Leadartis portfolio has a solid international intellectual property rights that covers its technology platform. In Addition, over the last three yearsCDTI Innovationhas funded two highly innovative projects in the participating agencies international excellence as are the national centre for Oncological Research (CNIO), the institute of Carlos III Health (IISCIII) and the Hospital 12 de Octubre (H12O).
“ In the first, PERSEUS, general objective is to provide the basis for the selection of patients to clinical development of LEAD-452 (phase 1 and later) of the first immunotherapy in Trimerbody inmunoestimuladora configuration for the treatment of cancer. Thus, the project will implement effectively a new selection process for development in clinical environment LEAD-452. As A biological agent LEAD-452 improve emerging coste-beneficio partner inmuno-oncológicas therapies, with significant saving of resources for the national health system (SNS) ”.
The second project, "Trimerbodies ™ coestimuladores pan-tumorales to allergies against cancer ” sets out the main objective the development of a novel immunotherapy strategy based on the use of a biespecífico Trimerbody acting simultaneously on a critical mechanism of coestímulo and on a control point immune microenvironment next to the targeting of tumour deposits. This synergistic response will trigger a potent tumor. For this purpose has been used technology TrimerbodyTM Leadartis owned.
Business model
In 2014, Leadartis carried out a capital increase that has enabled us to diversify their investigations. Its business model is based essentially on the licence of LEAD-452 once completed the clinical trial of Phase I, to a global company, biopharmaceutical resources in the form of upfront payments and royalties, milestones that will be utlizados to grow as a company and continuing development of additional Trimerbodies its pipeline. It also provides services to third parties. With this practice, over the last three years has produced 500,000 euros and in 2025 plans to overcome the 600,000 euros.
“ despite our small dimension as a company, we maintain partnerships with various companies farmaceútico and want to enter new markets of United States, Asia and europe ”.
CDTIInnovation
The CDTI Innovation is the agency for financing innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology. The CDTI also supports the creation and consolidation of technology-based enterprises in Spain.
The centre for technological development and innovation, E.P.E. (CDTI) is a public entity under the ministry of Science, innovation and universities.
Further information,:
Office of the press
prensa@cdti.es
91-581.55.00
On The Internet
Website:www.cdti.es
In Linkedin:https :// www.linkedin.com/company/29815
X:https :// twitter.com/CDTI _ innovation
On Youtube:https :// www.youtube.com/user/CDTIoficial